These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 9331714

  • 1. Superantigenic activity produced by group A streptococcal isolates is neutralized by plasma from IVIG-treated streptococcal toxic shock syndrome patients.
    Norrby-Teglund A, Low DE, McGeer A, Kotb M.
    Adv Exp Med Biol; 1997; 418():563-6. PubMed ID: 9331714
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome.
    Darenberg J, Söderquist B, Normark BH, Norrby-Teglund A.
    Clin Infect Dis; 2004 Mar 15; 38(6):836-42. PubMed ID: 14999628
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Streptococcal toxic shock syndrome (STSS). An update: a roundtable presentation.
    Holm SE, Köhler W, Kaplan EL, Schlievert PM, Alouf JE, Stevens DL, Kotb M.
    Adv Exp Med Biol; 1997 Mar 15; 418():193-9. PubMed ID: 9331631
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Novel superantigens from streptococcal toxic shock syndrome Streptococcus pyogenes isolates.
    Newton D, Norrby-Teglund A, McGeer A, Low DE, Schlievert PM, Kotb M.
    Adv Exp Med Biol; 1997 Mar 15; 418():525-9. PubMed ID: 9331707
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Invasive group A streptococcal disease. Association with a lack of anti-exotoxin antibodies.
    Mascini EM, Hazenberg MM, van Dalen A, Verhoef-Verhage LA, van Leeuwen NJ, Verhoef J, van Dijk H.
    Adv Exp Med Biol; 1997 Mar 15; 418():921-2. PubMed ID: 9331799
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome.
    Eriksson BK, Andersson J, Holm SE, Norgren M.
    J Infect Dis; 1999 Aug 15; 180(2):410-8. PubMed ID: 10395857
    [Abstract] [Full Text] [Related]

  • 16. In vivo and in vitro detection of a superantigenic toxin Vbeta signature in two forms of streptococcal toxic shock syndrome.
    Thomas D, Perpoint T, Dauwalder O, Lina G, Floccard B, Richard JC, Bouvet A, Peyramond D, Allaouchiche B, Chidiac C, Vandenesch F, Etienne J, Ferry T.
    Eur J Clin Microbiol Infect Dis; 2009 Jun 15; 28(6):671-6. PubMed ID: 19020908
    [Abstract] [Full Text] [Related]

  • 17. Rationale for the use of intravenous gamma globulin in the treatment of streptococcal toxic shock syndrome.
    Stevens DL.
    Clin Infect Dis; 1998 Mar 15; 26(3):639-41. PubMed ID: 9524836
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.